SLC5A2 and diabetic ketoacidosis: Some case reports concluded that treatment with SGLT2 inhibitors may be associated with an increased risk of euglycemic diabetic ketoacidosis, triggered by some factors such as severe insulin deficiency, low carbohydrate diet, alcohol intake, dehydration or some severe diseases [21].